- Melanoma metastes, single and in transit
- Breast cancer metastasis
- Basal and Squamous Cell Carcinoma
- Head and Neck
The effectiveness of electroporation in skin tumours ablation clinically has been reported by a growing deal of clinical studies with an over 80% objective response rate observed.
This new electroporation treatment approach is brought directly to the target by an ergonomic handle needle electrode array. The electroporation energy is delivered via a patented new painless waveform generated by the ePore device inducing cells to become porous or leaky for several minutes.
Specifically, the clinical values of the electroporation treatment are:
- Efficacy. Electroporation treatment in combination with chemotherapy has been investigated in a controlled manner, in a multicentre, prospective international clinical trials, demonstrating a complete tumour response of with a single treatment and an objective response of 85%.
- Haemorrhagic nodules stop bleeding immediately after electroporation treatment.
- Long-lasting response. Electroporation induces a high percentage of long-lasting local remission.
- Improves patients’ quality of life: wound healing, wound bleeding, aesthetics, daily activity, better social relations, pain relief, overall satisfaction and acceptance of the treatment.